¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"thyroid carcinoma risk factors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • islet cell carcinoma
    ¼¶¼¼Æ÷¾ÏÁ¾
  • inflammatory carcinoma
    ¿°ÁõÇü¾ÏÁ¾
  • intraductal carcinoma
    °ü³»¾ÏÁ¾
  • intraepithelial carcinoma
    »óÇdz»¾Ï(Á¾)
  • large cell carcinoma
    ´ë¼¼Æ÷¾ÏÁ¾, Å«¼¼Æ÷¾ÏÁ¾
  • mucinous carcinoma
    Á¡¾×¾ÏÁ¾
  • medullary carcinoma
    ¼ÓÁú¾ÏÁ¾, ¼öÁú¾ÏÁ¾
  • metaplastic carcinoma
    È­»ý¾ÏÁ¾
  • metastatic carcinoma
    ÀüÀ̾ÏÁ¾
  • microcystic carcinoma
    ¹Ì¼¼³¶¾ÏÁ¾
  • microinvasive carcinoma
    ¹Ì¼¼Ä§À±¾ÏÁ¾
  • neuroendocrine carcinoma
    ½Å°æ³»ºÐºñ¾ÏÁ¾
  • non-small cell carcinoma
    ºñ¼Ò¼¼Æ÷¾ÏÁ¾
  • nasopharyngeal carcinoma
    ÄÚÀεξÏÁ¾
  • oat cell carcinoma
    ±Í¸®¼¼Æ÷¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • basal cell carcinoma
    ¹Ù´Ú¼¼Æ÷¾ÏÁ¾, ±âÀú¼¼Æ÷¾ÏÁ¾
  • basosquamous cell carcinoma
    ¹Ù´ÚÆíÆò¼¼Æ÷¾ÏÁ¾, ±âÀúÆíÆò¼¼Æ÷¾ÏÁ¾
  • bronchioloalveolar carcinoma
    ¼¼±â°üÁöÆóÆ÷¾ÏÁ¾, ¼¼±â°üÁö²Ê¸®¾ÏÁ¾
  • bronchogenic carcinoma
    ±â°üÁöÀ¯·¡¾ÏÁ¾
  • carcinoma
    ¾ÏÁ¾
  • carcinoma in situ
    »óÇdz»¾ÏÁ¾
  • clear cell carcinoma
    Åõ¸í¼¼Æ÷¾ÏÁ¾
  • comedo carcinoma
    (¢¡comedocarcinoma) ¸éÆ÷¾ÏÁ¾
  • corpus carcinoma
    ÀڱøöÅë¾ÏÁ¾, ÀÚ±ÃüºÎ¾ÏÁ¾
  • duct carcinoma
    °ü¾ÏÁ¾
  • duct cell carcinoma
    °ü¼¼Æ÷¾ÏÁ¾
  • eccrine carcinoma
    ¿¡Å©¸°¶¡»ù¾ÏÁ¾
  • embryonal carcinoma
    ¹è¾Æ¾ÏÁ¾
  • epidermoid carcinoma
    (¢¡squamous cell) ÆíÆò¼¼Æ÷¾ÏÁ¾
  • follicular carcinoma
    °©»ó»ù¼ÒÆ÷¾ÏÁ¾, ¼ÒÆ÷¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • primary cutaneous adenocystic carcinoma
    ¿ø¹ß¼º ÇǺΠ¼±³¶Á¾¼º¾Ï
  • primary hepatic carcinoma
    ¿ø¹ß(¼º) °£¾ÏÁ¾(ê«Û¡(àõ) ÊÜäßðþ)
  • prostate carcinoma
    Àü¸³¼±¾ÏÁ¾(îñí¡àÍäßðþ)
  • prostate,grading of prostate carcinoma
    Àü¸³¼±¼±¾ÏÁ¾µî±Þ(îñí¡àÍàÍäßðþÔõÐä)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • isthmus of thyroid gland
    °©»ó¼± ÇùºÎ
  • isthmus of thyroid gland
    °©»ó¼±(Ë£ßÒàÍ)ÇùºÎ.
  • isthmus of thyroid gland
    °©»ó»ùÀß·è
  • lateral thyroid
    ¿ÜÃø°©»ó¼±(¿ÜÃø°©»ó¼±).
  • lateral thyroid
    ¿ÜÃø°©»ó¼±(èâö°Ë£ßÒàÍ).
  • levator muscle of thyroid gland<³ª> musculus leva tor grandulae thyr(e)oideae
    °©»ó¼±(°©»ó¼±)°Å±Ù.
  • levator muscle of thyroid gland<³ª> musculus leva tor grandulae thyr(e)oideae
    °©»ó¼±(Ë£ßÒàÍ)°Å±Ù.
  • lingual thyroid
    ¼³°©»ó¼±
  • lingual thyroid
    ¼³°©»ó¼±(àßË£ßÒàÍ).
  • lingual thyroid gland
    Çô°©»ó»ù
  • lobules thyroid gland
    °©»ó»ù¼Ò¿±, °©»ó¼±(Ë£ßÒàÍ)¼Ò¿±.
  • long acting thyroid stimulator =LATS
    Àå±âÀÛ¿ë°©»ó¼±Àڱع°Áú(íþÑ¢íÂéÄ Ë£ßÒàÍô§Ð½Úªòõ).
  • long-acting thyroid stimulator
    Àå½Ã°£ÀÛ¿ë°©»ó¼±ÀÚ±ØÀÎÀÚ
  • lowest thyroid artery
    ÃÖ(ÇÏ)ºÎ°©»ó¼±µ¿¸Æ (õÌù»ÜùË£ßÒàÍÔÑØæ).
  • lowest thyroid artery <³ª> arteria thyr(e)oidea ima
    ÃÖÇϰ©»ó¼±µ¿¸Æ (ÃÖÇϰ©»ó¼±µ¿¸Æ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
EC effective concentration; ejection click; electrochemical; electron capture; embryonal carcinoma; eme...
SCC self-care center; sequential combination chemotherapy; services for crippled children; short-course ...
ANF Atrial Natriuretic Factors
ECF   1) Eosinophilic Chemotatic Factors
  2) Extra-Cellular Fluid; ¼¼Æ÷ ¿Ü¾×
NCF Neutrophilic Chemotatic Factors
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MRF Monoclonal rheumatoid factors
MCF Mononuclear cell factors
NTF Neurotrophic factors
OAF Osteoclast activating factors
RF Release factors
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • columnar cell carcinoma
    ¿øÁÖ ¼¼Æ÷ ¾ÏÁ¾
  • cutaneous metastatic carcinoma
    ÇǺΠÀüÀÌ ¾Ï, ÇǺΠÀüÀÌ ¾ÏÁ¾
  • duct carcinoma
    °ü ¾ÏÁ¾
  • embryonal carcinoma
    ¹è¾Æ¼º ¾ÏÁ¾
    °íȯ¿¡ »ý±â´Â °°Àº Á¾·ùÀÇ ¾ÏÁ¾º¸´Ù´Â ´ú ÈçÈ÷ ³­¼Ò¿¡ ¹ß»ýÇÏ°í ¾î¸°ÀÌ¿Í ÀþÀº ¿©¼º¿¡ È£¹ßÇÑ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¹Ì¼º¼÷ »óÇÇ ¼¼Æ÷µéÀÌ ¹Ì¸¸¼º ¶Ç´Â ¼±»ó ÇüÅ·Π¹è¿­µÈ´Ù. À¶ÇÕ ¼¼Æ÷ ¿µ¾ç¸· °Å´ë ¼¼Æ÷°¡ ´ëºÎºÐ ÃâÇöÇÏ¿© HCG¿¡ ¾ç¼ºÀ̰í Å»ý±â ¾Ï ¼¼Æ÷´Â ¾ËÆÄ ÅÂ¾Æ ´Ü¹é¿¡ ¾ç¼ºÀÌ´Ù.
  • endometrial carcinoma
    Àڱà ³»¸· ¾ÏÁ¾
    ÇϳªÀÇ ±ºÀº Áö¼ÓÀûÀÎ ¿¡½ºÆ®·Î°Õ Àڱذú Àڱ󻸷 °úÇü¼ºÀÇ ¹è°æ¿¡¼­ ¹ß»ýÇÑ´Ù´Â °ÍÀÌ´Ù. Àڱ󻸷 °úÇü¼º°ú ¾ÏÁ¾Àº ºñ¸¸°ú ¹«¹è¶õ ÁÖ±â¿Íµµ À¯°üÇÏ´Ù. ÀÌ·¯ÇÑ ÀÎÀÚµé°ú ¿¬°üµÇ¾î ¹ß»ýÇÑ ³»¸· ¾ÏÀº ºÐÈ­°¡ ÁÁÀº °æÇâÀÌ ÀÖ°í ÇüÅÂÇÐÀûÀ¸·Î Á¤»ó ³»¸·¼±°ú À¯»çÇÑ "Àڱ󻸷¾ç
  • epithelial carcinoma
    »óÇÇ ¾ÏÁ¾
  • fibrosing basal cell carcinoma
    ¼¶À¯¼º ±âÀú ¼¼Æ÷ ¾Ï
  • infiltrating duct breast carcinoma
    ħÀ±¼º °ü»ó À¯¹æ ¾Ï
  • intraductal carcinoma
    ¼±°ü³» ¾Ï
  • invasive carcinoma
    ħ½À¼º ¾ÏÁ¾
  • invasive squamous cell carcinoma
    ħÀÔ¼º ÆíÆò »óÇÇ ¼¼Æ÷ ¾Ï
  • inverted nipples breast carcinoma
    ÇÔ¸ô À¯µÎ À¯¹æ ¾Ï
  • laryngeal carcinoma
    ÈĵξÏ
    Èĵο¡ ¹ß»ýÇÏ´Â ¾Ï. 95 % ÀÌ»óÀÌ Á¶Á÷ÇÐÀûÀ¸·Î ÆíÆò »óÇǾÏ
  • latent carcinoma
    ÀáÀ缺 ¾Ï
    ºÐ¸íÈ÷ ¾ÏÀÌÁö¸¸ ÀÓ»óÀûÀ¸·Î Áõ»óÀÌ ¾øÀ¸¸ç, ¿¬·É Áõ°¡ ½Ã ÇÔ²² Áõ°¡ÇÑ´Ù.
  • lobular breast carcinoma in situ
    ¼Ò¿±¼º, ºñħÀ±¼º À¯¹æ ¾Ï
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
stem cell growth factors <growth factor> Compounds, usually proteins, that make stem cells grow faster.
(26 Mar 1998)
nerve growth factors Factors which enhance the growth potentialities of sensory and sympathetic nerve cells.
(12 Dec 1998)
debranching factors Enzyme's that bring about destruction of branches in glycogen; formerly considered to be one enzyme, now known to be a mixture of transferases (4-alpha-d-glucanotransferase) and hydrolases (amylo-1,6-glucosidase).
Synonym: debranching factors.
(05 Mar 2000)
suppressor factors, immunologic Proteins, protein complexes, or glycoproteins secreted by suppressor T-cells that inhibit either subsequent T-cells, B-cells, or other immunologic phenomena. Some of these factors have both histocompatibility (I-j) and antigen-specific domains which may be linked by disulfide bridges. They can be elicited by haptens or other antigens and may be mass-produced by hybridomas or monoclones in the laboratory.
(12 Dec 1998)
direct lytic factors most abundant proteins in cobra (naja of the elapids) venom; basic polypeptides of 57 to 62 amino acids with four disulfide bonds and a molecular weight of less than 7000; causes skeletal and cardiac muscle contracture, interferes with neuromuscular and ganglionic transmission, depolarises nerve, muscle and blood cell membranes, thus causing haemolysis.
Synonym: cobramine a; cobramine b; cobra cytotoxin; gamma toxin; membrane-active polypeptide.
(12 Dec 1998)
immunologic and biological factors A collective grouping for biologically active substances that play a role in the functioning of the immune system and those that show biological or physiological activity.
(12 Dec 1998)
immunologic factors Biologically active substances whose activities affect or play a role in the functioning of the immune system.
(12 Dec 1998)
initiation factors The set of catalytic proteins required, in addition to mRNA and ribosomes, for protein synthesis to begin. In bacteria three distinct proteins have been identified: if 1 (8 kD), IF 2 (75 kD) and IF 3 (30 kD). at least 6-8 proteins have been identified in eukaryotes. IFs 1 and 2 enhance the binding of initiator tRNA to the initiation complex.
(18 Nov 1997)
insulin-like growth factors Peptides whose formation is stimulated by growth hormone. These peptides bring about peripheral tissue effects of that hormone and have high (about 70%) homology to human insulin.
Synonym: somatomedins.
(05 Mar 2000)
ischemia-modifying factors Various factors that play a role in determining the extent of necrosis with cerebral stroke; these include blood viscosity and osmolality, the blood pressure, and the anatomy of the neck and intracranial arteries.
(05 Mar 2000)
time factors Elements of limited time intervals, contributing to particular results or situations.
(12 Dec 1998)
transcription factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
(12 Dec 1998)
transcription factors, tfii The so-called general transcription factors that bind to RNA polymerase II and that are required to initiate transcription. They include tfiia, tfiib, tfiid, tfiie, tfiif, tfiih, tfii-I, and tfiij. In vivo they apparently bind in an ordered multi-step process and/or may form a large preinitiation complex called RNA polymerase II holoenzyme.
(12 Dec 1998)
transcription factors, tfiii Factors that bind to RNA polymerase III and aid in transcription. They include the assembly factors tfiiia and tfiiic and the initiation factor tfiiib. All combine to form a preinitiation complex at the promotor that directs the binding of RNA polymerase III.
(12 Dec 1998)
transforming growth factors <chemical> Hormonally active polypeptides that can induce the transformed phenotype when added to normal, non-transformed cells. They have been found in culture fluids from retrovirally transformed cells and in tumour-derived cells as well as in non-neoplastic sources. Their transforming activities are due to the simultaneous action of two otherwise unrelated factors, transforming growth factor alpha and transforming growth factor beta.
Chemical name: Animal growth regulators, transforming growth factors
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á